comparemela.com
Home
Live Updates
Blue Note Therapeutics and Bixink Enter Licensing Agreement
Blue Note Therapeutics and Bixink Enter Licensing Agreement
Blue Note Therapeutics and Bixink Enter Licensing Agreement for attune™ and DreAMLand™, Prescription
SAN FRANCISCO - May 9, 2022 - (Newswire.com) Blue Note Therapeutics and Bixink Therapeutics, a bio-subsidiary of KPS, today announced that the companies have entered into an exclusive lic...
Related Keywords
South Korea ,
South Korean ,
Geoffrey Eich ,
Mikyoung Hahn ,
Kim King ,
Drug Administration ,
Bixink Therapeutics Co ,
Note Therapeutics ,
Bixink Therapeutics ,
Blue Note ,
Blue Note Therapeutics ,
Breakthrough Device Designation ,
Breakthrough Device ,
South Korean Bio Company ,
Release Service ,
Bixink Enter Licensing Agreement ,
Prescription Digital Therapeutics ,
Mental Well Being ,